Literature DB >> 11812440

Management options for early stages of acutely symptomatic macular holes.

Gregg T Kokame1.   

Abstract

PURPOSE: To evaluate management options for acutely symptomatic stage I macular holes, and vitrectomy with intraocular gas tamponade for advanced stage I macular holes.
METHODS: Retrospective noncomparative study.
SETTING: Clinical practice. STUDY POPULATION: Acutely symptomatic stage I macular holes. MANAGEMENT OPTIONS: (I) spontaneous resolution with observation -7 eyes; (II) stage I holes developing poor visual acuity of 20/50 or worse during observation -9 eyes undergoing pars plana vitrectomy, posterior vitreous separation, fluid -20% sulfur hexafluoride gas exchange; (III) stage I holes acutely progressing to stage II or III during observation -9 eyes with vitrectomy, posterior vitreous separation, membrane peel, fluid -18% perfluoropropane gas exchange. MAIN OUTCOME MEASURES: visual acuity of 20/40 of better, prevention, or closure of macular hole.
RESULTS: Spontaneous resolution developed in 7 eyes with 20/40 or better vision (group I). 8/9 eyes undergoing vitrectomy for advanced stage I holes (group II) did not progress and recovered 20/40 or better vision. 1/9 recovered 20/40 vision after further surgery. 9/9 eyes following acute progression to full-thickness holes (group III) had closed macular holes with recovery of 20/40 vision after vitrectomy.
CONCLUSIONS: Stage I macular holes can initially be observed. However, excellent visual and surgical results can be obtained in stage I holes with poor vision, or with acute progression to full-thickness holes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812440     DOI: 10.1016/s0002-9394(01)01266-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  1 in total

1.  [Diagnosis and evaluation of macular hole with the HRT 2 retina module].

Authors:  Z Michalewska; J Michalewski; J Nawrocki
Journal:  Ophthalmologe       Date:  2007-10       Impact factor: 1.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.